RGNX
REGENXBIO Inc.
NASDAQ · USHealthcareBiotechnology
$10.32+4.35%
Price as of Jul 20, 2026
RGNX valuation
REGENXBIO Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 3.01x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 25.31x
- Price / sales
- 6.08x
- Price / cash flow
- -2.28x
Enterprise value
- Enterprise value
- $454.1M
- EV / sales
- 5.17x
- EV / EBITDA
- -1.98x
- EV / EBIT
- -1.77x
- Market cap
- $533.5M
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.